Jiangxi Starry Pharmaceutical Co., Ltd.,

 

Founded in 2011 in the Salt Chemical Industry Base in Zhangshu City, Jiangxi Starry Pharmaceutical Co., Ltd., covering an area of 300 mu, is a national high-tech enterprise engaged in research and development, manufacturing and sales of X-CT contrast agent intermediates, nuclear magnetic resonance bulk drugs and customized products (CMO). The company has more than 300 employees and a registered capital of RMB 68 million. Its controlling shareholder is the listed company Starry Pharm.

 

　　Adhering to the concept of innovation and development, the company has a relatively perfect technology management and research and development system. Under the guidance of the quality concept of "quality is life and quality is our guarantee", the company has built a high-level comprehensive quality testing center and introduced excellent talents and imported advanced equipment from Japan, the United States and other countries. At the same time, using scientific testing methods and highly compliant management software, the company has strictly controlled the quality of products and occupied a leading advantageous position in the market. The company insists on green recycling development, invests in the construction of sewage treatment stations, and kicks off RTO project so as to improve its waste water and waste gas treatment capacity. RTO is a pioneering project in Yichun and even Jiangxi. It is a useful exploration for waste gas treatment in the whole province to ensure the safe development and green rise of enterprises.

 

　　Basing its development in Jiangxi, the company has successively won Yichun Excellent Enterprise Award and Zhangshu Tax Contribution Award. Its products are exported to well-known pharmaceutical companies in Japan, France, etc. The company has expanded its market to Europe, North America, South America, and has established long and good cooperative relations with both domestic and foreign customers. In 2018, the company reached a strategic partnership with France-based Guerbet, one of the four major international contrast agents original research enterprises, developing its unique advantages and strong competitiveness in the field of contrast agent upstream products.

 

 

　　展望未来，江西司太立将继续践行“聚合生命能量、呵护人类健康”的主题理念，立足国内，放眼全球，不断做大做强，力争把公司打造成为江西乃至全国独特的、可持续发展的、富有竞争力的医药制造公司。